Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia

European Respiratory Journal

Volumn 34, Issue 2, 2009, Pages 394-400

  Scaglione, F ^a   Esposito, S ^b   Leone, S ^b   Lucini, V ^a   Pannacci, M ^a   Ma, L ^c   Drusano, G L ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Nosocomial pneumonia; Optimising antibiotic therapy; Pharmacokinetic pharmacodynamic indices

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NOSOCOMIAL PNEUMONIA; PARAMETER; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; SCORING SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 69249130551     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00149508     Document Type: Article

References (17)

1. American Thoracic Society, Infectious Diseases Society of America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
2. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-903.
3. Heyland DK, Cook DJ, Griffith L, et al. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999; 159: 1249-1256.
4. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31: Suppl. 4, S131-S138.
5. Scaglione F, Paraboni L. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Anti Infect Ther 2006; 4: 479-490.
6. Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483-490.
7. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of "bug and drug". Nat Rev Microbiol 2004; 2: 289-300.
8. Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 2002; 19: 349-353.
9. Preston SL, Drusano GL, Berman AL, et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother 1998; 42: 1098-1104.
10. Forrest A, Ballow CH, Nix DE, et al. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993; 37: 1065-1072.
11. National Committee for Clinical Laboratory Standards (NCCLS)., Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. NCCLS document M2-A7. Wayne, NCCLS, 2000.
12. Wong FA, Juzwin SJ, Flor SC. Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine. J Pharm Biomed Anal 1997; 15: 765-771.
13. Mack G. Improved high-performance liquid chromatographic determination of ciprofloxacin and its metabolites in human specimens. J Chromatogr 1992; 582: 263-267.
14. Kraemer HJ, Gehrke R, Breithaupt A, et al. Simultaneous quantification of cefotaxime, desacetylcefotaxime, ofloxacine and ciprofloxacine in ocular aqueous humor and in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 700: 147-153.
15. Hanes SD, Herring VL, Wood GC. Alternative method for determination of ceftazidime in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998; 719: 245-250.
16. MacGowan AP. Role of pharmacokinetics and pharmacodynamics: does the dose matter? Clin Infect Dis 2001; 33: Suppl. 3, 238-239.
17. Barger A, Fuhst C, Wiedemann B. Pharmacological indices in antibiotic therapy. J Antimicrob Chemother 2003; 52: 893-898.